|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Aging (NIA) |
|---|---|
| Information provided by: | National Institute on Aging (NIA) |
| ClinicalTrials.gov Identifier: | NCT00000178 |
Purpose
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
| Condition | Intervention | Phase |
|---|---|---|
|
Alzheimer Disease |
Drug: Prednisone |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study |
| Official Title: | Multicenter Trial of Prednisone in Alzheimer's Disease |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Alabama | |
| University of Alabama, Birmingham | |
| Birmingham, Alabama, United States, 35294-0017 | |
| United States, California | |
| University of Southern California | |
| Los Angeles, California, United States, 90033 | |
| University of California, San Diego | |
| San Diego, California, United States, 92093-0949 | |
| United States, Florida | |
| Mayo Clinic Jacksonville | |
| Jacksonville, Florida, United States, 32225 | |
| University of Miami | |
| Miami, Florida, United States, 33140 | |
| University of South Florida | |
| Tampa, Florida, United States, 33162 | |
| United States, Indiana | |
| Indiana University Alzheimer's Center | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Kansas | |
| University of Kansas Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21224 | |
| United States, Minnesota | |
| University of Minnesota | |
| Minneapolis, Minnesota, United States, 55455 | |
| United States, Missouri | |
| Washington University | |
| St. Louis, Missouri, United States, 63110 | |
| United States, New York | |
| Mount Sinai Medical Center | |
| New York, New York, United States, 10029 | |
| Columbia Presbyterian Medical Center | |
| New York, New York, United States, 11032 | |
| New York University Medical Center | |
| New York, New York, United States, 10016 | |
| University of Rochester | |
| Rochester, New York, United States, 14620 | |
| Burke Medical Research Institute | |
| White Plains, New York, United States, 10605 | |
| United States, Pennsylvania | |
| University of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37212-8646 | |
| United States, Texas | |
| University of Texas | |
| Dallas, Texas, United States, 75235-9070 | |
| Principal Investigator: | Leon Thal, MD. | University of California, San Diego |
More Information
| Study ID Numbers: | IA0002, 3U01AG10483-08S2 |
| Study First Received: | October 29, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000178 History of Changes |
| Health Authority: | United States: Federal Government |
|
Alzheimer's disease Prednisone Anti-inflammatory agents |
|
Anti-Inflammatory Agents Prednisone Antineoplastic Agents, Hormonal Antineoplastic Agents Physiological Effects of Drugs Alzheimer Disease Nervous System Diseases Hormones, Hormone Substitutes, and Hormone Antagonists Central Nervous System Diseases Brain Diseases |
Neurodegenerative Diseases Hormones Glucocorticoids Pharmacologic Actions Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Therapeutic Uses Dementia Tauopathies |